|  |
| --- |
| S1 Table. Characteristics of breast cancer patients by tumor subtypes |
|   | HR+ HER2- |  HR+ HER2+  |  HR- HER2+  |  HR- HER2-  |
|  | Discovery |  Replication  |  Discovery  |  Replication  |  Discovery  | Replication |  Discovery  |  Replication  |
|   | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| No. of patients |  995  | (100.0) |  907  | (100.0) |  241  | (100.0) |  162  | (100.0) |  221  | (100.0) |  146  | (100.0) |  275  | (100.0) |  279  | (100.0) |
| Median follow-up time, years (range) | 4.0 | (0.3-8.8) | 4.6 | (0.3-8.5) | (3.5) | (0.5-8.5) | 4.8 | (0.3-8.4) | 3.5 | (0.4-8.4) | 4.5 | (0.3-8.5) | 3.5 | (0.3-8.5) | 4.3 | (0.3-8.5) |
| Total time at risk, person-years | 4139.3 | 4137.9 | 972.3 | 756.5 | 841.4 | 632.7 | 1025.3 | 1150.7 |
| Recurrence | 91  | (9.2) | 68  | (7.5) | 26  | (10.8) | 28  | (17.3) | 36  | (16.3) | (29.0) | (19.9) | 61  | (22.2) | 39  | (14.0) |
| Death | 37  | (3.7) | 22  | (2.4) | 15  | (6.2) | 11  | (6.8) | 20  | (9.1) | (14.0) | (9.6) | 33  | (12.0) | 25  | (9.0) |
| Median age at surgery, years (range) | 47  | (26-80) | 47  | (21-82) | 46  | (28-70) | 44  | (25-65) | 49  | (30-79) | (50.0) | (28-82) | 46  | (26-82) | 46  | (21-78) |
| Tumor size |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  ≤2 cm | 581  | (58.4) | 544  | (60.0) | 132  | (54.8) | 77  | (47.5) | 124  | (56.1) | (65.0) | (44.5) | 105  | (38.2) | 445  | (40.1) |
|  2-5 cm | 345  | (34.7) | 335  | (36.9) | 82  | (34.0) | 75  | (46.3) | 76  | (34.4) | (76.0) | (52.1) | 145  | (52.7) | 485  | (54.5) |
|  >5 cm | 40  | (4.0) | 23  | (2.5) | 19  | (7.9) | 9  | (5.6) | 17  | (7.7) | (5.0) | (3.4) | 22  | (8.0) | 47  | (5.0) |
| Nodal status |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  negative | 624  | (62.7) | 572  | (63.1) | 144  | (59.8) | 88  | (54.3) | 136  | (61.5) | (92.0) | (63.0) | 155  | (45.4) | 181  | (64.9) |
|  positive | 371  | (37.3) | 335  | (36.9) | 97  | (40.3) | 74  | (45.7) | 85  | (38.5) | (54.0) | (37.0) | 120  | (43.6) | 98  | (35.1) |
| TNM stage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  0-I | 482  | (48.4) | 403  | (44.4) | 107  | (44.4) | 56  | (34.6) | 98  | (44.3) | (47.0) | (32.2) | 76  | (27.6) | 89  | (31.9) |
|  II | 384  | (38.6) | 404  | (44.5) | 88  | (36.5) | 80  | (49.4) | 77  | (34.8) | (80.0) | (54.8) | 145  | (52.7) | 141  | (50.5) |
|  III | 129  | (13.0) | 100  | (11.0) | 46  | (19.1) | 26  | (16.1) | 46  | (20.8) | (19.0) | (13.0) | 54  | (19.6) | 49  | (17.6) |
| ER status |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  positive | 880  | (88.4) | 794  | (87.5) | 189  | (78.4) | 127  | (78.4) | 0  | (0.0) | (0.0) | (0.0) | 0  | (0.0) | 0  | (0.0) |
|  negative | 115  | (11.6) | 113  | (12.5) | 52  | (21.6) | 35  | (21.6) | 221  | (100.0) | (146.0) | (100.0) | 275  | (100.0) | 279  | (100.0) |
| PR status |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  positive | 751  | (75.5) | 670  | (73.9) | 185  | (76.8) | 108  | (66.7) | 0  | (0.0) | (0.0) | (0.0) | 0  | (0.0) | 0  | (0.0) |
|  negative | 241  | (24.2) | 236  | (26.0) | 56  | (23.2) | 53  | (32.7) | 221  | (100.0) | (146.0) | (100.0) | 275  | (100.0) | 279  | (100.0) |
| HER2 status |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  negative | 0  | (0.0) | 0  | (0.0) | 241  | (100.0) | 162  | (100.0) | 221  | (100.0) | (146.0) | (100.0) | 0  | (0.0) | 0  | (0.0) |
|  positive | 995  | (100.0) | 907  | (100.0) | 0  | (0.0) | 0  | (0.0) | 0  | (0.0) | (0.0) | (0.0) | 275  | (100.0) | 279  | (100.0) |

Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.